Important Notice Regarding Euthyrox^® Availability in the U.S.

Provell Pharmaceuticals LLC, our former U.S. commercial partner for Euthyrox^® (levothyroxine sodium), has ceased the commercialization of the product in the US. The Marketing Authorization for Euthyrox^® has been transferred to EMD Serono, Inc., effective April 2025. The last expiration date of the finished product currently on the market in the U.S. is September 2026. Potential shortages may occur.  
Different options are being evaluated for identifying a new distribution partner to minimize disruption and to ensure continued product availability. Please note that this change does not affect the quality, formulation, efficacy, or safety of Euthyrox^®. 
We encourage healthcare professionals to proactively discuss treatment continuity and alternative options with patients if needed.  
For more information, please contact our Medical Information team through this website or at: 
Phone: 1-888-275-7376 (Mon-Fri, 8:00 AM – 5:30 PM ET)
Email: emediusa@emdserono.com

Investigational agents and investigational indications for marketed products are under clinical investigation and have not been proven to be safe and effective. There is no guarantee that any product will be approved in the sought-after indication.